Postmortem studies in schizophrenia by Harrison, Paul J.
For over a century, postmortem studies have played a
central part in the search for the structural and bio-
chemical pathology of schizophrenia. However, for most
of this time, little progress has been made. Recently, the
situation has begun to change, helped by the emergence
of more powerful methodologies and research designs,
and by the availability of brain imaging to provide com-
plementary information. As a result, it can now be clearly
concluded that there are structural cerebral abnormalities
in schizophrenia that are intrinsic to the disorder. The
neuropathological process is not primarily degenerative,
but involves a change in the normal cytoarchitecture of
the brain, probably originating in development. Neuro-
chemically, there is postmortem evidence for alterations
in several transmitter systems including dopamine, glu-
tamate, serotonin, and  -aminobutyric acid (GABA). The
cardinal findings are reviewed here, together with a con-
sideration of the conceptual and methodological issues
that face postmortem studies of schizophrenia. 
ust over 100 years ago,Kraepelin,convinced
that schizophrenia was an organic brain disease, per-
suaded Alzheimer to carry out the first neuropatho-
logical investigation. However, no robust findings
emerged from this or any other postmortem study for
over half a century, leading, in 1972, to the oft-quoted
aphorism that schizophrenia is the “graveyard of neu-
ropathologists,”
1 a statement which,together with crit-
ical reviews,
2,3 marked the nadir of the field. Over the
past 30 years, unequivocal signs of life have appeared
in the graveyard,allowing Ron and Harvey
4 to charge
that “to have forgotten that schizophrenia is a brain
disease will go down as one of the great aberrations of
twentieth century medicine,”and Weinberger
5 to state
“20 years ago, the principal challenge for schizophre-
nia research was to gather objective scientific evidence
that would implicate the brain. That challenge no
longer exists.”The current challenge is to establish the
characteristics of the pathological changes, which
remain far from clear.
6,7Attempts to elucidate the neu-
rochemistry of schizophrenia from postmortem studies
have also proved difficult, but progress is being made
in this area too.This review summarizes the key recent
neuropathological and neurochemical findings.It also
considers the main issues affecting the field, and its
prospects for the future.
Macroscopic brain changes 
in schizophrenia
Although early postmortem studies and pneumoen-
cephalography had provided some relevant data, it
was the advent of computed tomography (CT) and
magnetic resonance imaging (MRI) that led to the
clear demonstration of macroscopic brain changes
associated with schizophrenia.There have now been a
large number of increasingly sophisticated and
detailed imaging studies, and recently several meta-
analyses and systematic reviews, which allow the car-
dinal changes to be identified.
8-11 These are summa-
rized in Table I, together with some of the other
findings that are of current interest, but that have not
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Basic researchbeen substantiated to the same extent.
12,13 Because the
focus of this paper is on postmortem studies,the imag-
ing literature is not discussed in detail. However, it is
noteworthy that it is the incontrovertible in vivo imag-
ing evidence that there is a pathology of schizophrenia
to be found which has driven the ongoing neu-
ropathological studies.
The imaging data have also allowed other important
conclusions to be drawn, which inform and bolster
postmortem research (Table II).
14-18 In particular, since
the structural changes are present at the time of dis-
ease onset and are, by and large, not progressive
thereafter (although there may well be exceptions to
this rule
17,19), it is reasonable to assume that the corre-
sponding histological abnormalities share this prop-
erty, even though it is in practice impossible to prove
this in postmortem studies. Instead, the latter can now
focus on the microscopic and molecular aspects of the
pathology, which remain out of reach of any imaging
modality.
Histological and molecular 
pathology of schizophrenia 
Contemporary histological studies have addressed two
main areas: first, to clarify the frequency and nature of
neurodegenerative abnormalities in schizophrenia; and,
second,to investigate the cellular organization (cytoarchi-
tecture) of the brain.A summary of the most established
and the most often cited findings is given in Table III.
Gliosis and neurodegeneration 
The two most robust and important findings concern-
ing the neuropathology of schizophrenia are both nega-
tive: there is no excess of gliosis, or of Alzheimer’s dis-
ease or other neurodegenerative pathology.
The issue of gliosis (reactive astrocytosis) has been
extensively investigated since a report that gliosis was
common in schizophrenia,especially in the diencephalon
around the third ventricle.
20 As gliosis is a sign of past
inflammation, this invoked scenarios for schizophrenia
involving infective, ischemic, autoimmune, or neurode-
generative processes.However,over a dozen subsequent
investigations using more quantitative methods have not
replicated this observation, and the consensus is now
that gliosis is not a feature of schizophrenia.
21 The issue
is complicated by the excess of nonspecific and focal
abnormalities, including gliosis, seen in brain series of
schizophrenia; however, this is likely to be an epiphe-
nomenon not an intrinsic finding
21,22 and, importantly,
decreased brain size is still seen after omission of all
such brains.
23
Given the pathological implications of gliosis,its absence
in schizophrenia implies that none of the processes men-
tioned above are likely to be relevant to its pathogenesis.
Equally,the absence of gliosis has been attributed a par-
ticular positive significance: the gliotic response does
not begin until the second trimester in utero,and hence
an absence of gliosis is taken as prima facie evidence of
a disease process occurring before this time—and there-
fore is important support for prenatal neurodevelop-
mental models of schizophrenia.
24 Unfortunately, both
the absence of gliosis and its interpretation are less clear
than often assumed. First, detecting gliosis is surpris-
ingly difficult,and it can be argued that the data do not
wholly rule out its occurrence. Second, despite the
widely cited time point at which the glial response is
said to begin, the matter has not been well investigated
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Established by systematic reviews
• Enlargement of lateral and third ventricles (+25%–40%)
• Smaller brain volume (-3%)
• Smaller cortical volume (-4%) 
• Smaller gray matter volume (-6%)
• Relatively smaller medial temporal lobe volume (-5%)
• Relatively smaller thalamic volume (-4%)
• Larger basal ganglia (especially the globus pallidus)*
Other replicated findings
• Greater involvement of heteromodal association cortex 
• Decrease (or loss) of cerebral asymmetries
Table I. Macroscopic brain changes in schizophrenia.
* Due to antipsychotic medication.
Table II. Characteristics of structural imaging findings in schizophrenia.
Differences are readily apparent in discordant 
monozygotic twins
14
Differences are present in first-episode, untreated patients,
and in high-risk and unmedicated individuals
15
No convincing evidence of heterogeneity (eg, subtypes 
or gender differences), or clinicopathological correlations 
(eg, progression of changes), although this remains 
controversial
16,17
The alterations are not seen in bipolar disorder to 
the same extent, if at all
19351
and it is prudent not to use this to time the pathology of
schizophrenia with spurious accuracy.Third,it is a moot
point whether the subtle kinds of morphometric distur-
bance described in schizophrenia, whenever and how-
ever they occurred, would be sufficient to trigger
detectable gliosis.
It has been asserted that Alzheimer’s disease is com-
moner than expected in schizophrenia.This may have
arisen from the assumption that it explains the cogni-
tive impairment which is seen throughout the course of
schizophrenia
25 and which is both common and severe
in elderly patients.
26 However, a meta-analysis shows
that Alzheimer’s disease is not commoner, and may
even be rarer, in schizophrenia.
27 This applies even in
elderly schizophrenics with prospectively assessed
severe dementia, who show no evidence of any other
neurodegenerative disorder either.
28
Neural cytoarchitecture in schizophrenia 
If neurodegenerative abnormalities are uncommon in,or
epiphenomenal to, schizophrenia, it begs the questions
as to what the pathology is and how the macroscopic
findings are explained microscopically.The answer has
been sought in the cytoarchitecture of the cerebral cor-
tex, with measurements of parameters such as the size,
location, distribution, and packing density of neurons
and their synaptic connections (Table III).
Three cytoarchitectural alterations have generated par-
ticular interest: abnormal neuronal organization (dys-
plasia) in lamina II (pre-alpha cells) and lamina III of
the entorhinal cortex
29; disarray of hippocampal neu-
rons
30;and an altered distribution of neurons in the sub-
cortical white matter.
31 These findings are important
because they almost certainly reflect impairment of neu-
ronal migration and formation of the cytoarchitecture,
and hence strongly support the hypothesis of an early
neurodevelopmental anomaly underlying schizophre-
nia.
24,32 However, none has been unequivocally repli-
cated;for example,entorhinal cortex dysplasia has been
seen in some studies
33-35 but not others,
36-38 undermining
attempts to date the pathology of schizophrenia,as was
the case regarding interpretation of the lack of gliosis.
A less well-known yet somewhat more robust cytoar-
chitectural feature of schizophrenia is that many neu-
rons are decreased in size (ie, have a reduced cell body
area or volume).This has been shown in three studies of
pyramidal neurons in the hippocampus,
39-41 and has also
been reported in dorsolateral prefrontal cortex
42 and
cerebellar Purkinje cells.
43 Some studies found that the
neurons are also more closely packed.Outside the cere-
bral cortex,extensive cytoarchitectural data are limited
to the thalamus, for which there are reports of a loss of
neurons from the dorsomedial and anterior nuclei,
though the matter remains controversial.
Synapses and dendrites 
Synapses and dendrites represent a potential site for
pathologies that are undetectable using standard
approaches. Because they are hard to visualize directly,
proteins localized to these parts of the neuron are used
as markers for them.
44
Markers of presynaptic terminals are generally reduced
in the hippocampus in schizophrenia.
44,45The magnitude
of the loss varies according to the individual synaptic
proteins (and hippocampal subfields) studied, implying
that the synaptic pathology is not uniform.There is some
evidence for preferential involvement of excitatory con-
nections.
46 Presynaptic markers may also be reduced in
prefrontal cortex, but in this region it is a subset of
inhibitory neurons and terminals which appears most
affected.
47 Complementing these changes,alterations in
dendrites have been shown in the neocortex and in the
subiculum, with a decreased density of dendritic spines
seen in three studies.
48 Although unproven, the usual
and simplest interpretation is that these changes
together reflect fewer (or otherwise aberrant) synaptic
contacts being formed and received.
44,45,49
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Table III. Histological findings in schizophrenia.
0: no good evidence; +/-: equivocal data; + to +++++: increasing amounts of
supportive data. 
Weight of evidence
Lack of neurodegenerative lesions 
(eg, Alzheimer changes)
+++++
Lack of gliosis ++++
Smaller cortical and hippocampal 
pyramidal neurons
+++
Decreased cortical and hippocampal 
synaptic markers
+++
Decreased dendritic spine density ++
Loss of neurons from dorsal thalamus ++
Abnormalities of white matter neurons +
Entorhinal cortex dysplasia +
Disarray of hippocampal neuron orientation +/-
Loss of hippocampal or cortical neurons 0352
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There is an encouraging convergence between these
synaptic findings and the cytoarchitectural alterations.In
particular, the decreases in presynaptic and dendritic
markers are in keeping with the smaller neuronal cell
bodies, since the size of the latter is proportional to the
dendritic and axonal spread of the neuron.
50 It is also
consistent with an increased neuronal density, in that
dendrites and synapses comprise most of the neuropil
and, if this is reduced, neurons will pack more closely.
51
Moreover, it also corresponds with the results of pro-
ton magnetic resonance studies, which have shown
reductions in the neuronal marker N-acetylaspartate
(NAA),as one would predict if the neurons are on aver-
age smaller and have less extensive projections.
52
Where and what is the pathology?
Most of the positive findings reported in schizophre-
nia are in the hippocampal formation, dorsolateral
prefrontal cortex, and cingulate gyrus.
6,7 However,
this may be merely a sign that these areas have been
the most intensively studied. Few studies have
included a comparison region (eg, striate cortex), and
those which have do not provide a clear picture as
to the uniformity versus selectivity of cerebral
involvement in schizophrenia. Neither are any of the
individual histological abnormalities specific or
pathological in the sense that a neurofibrillary tangle
or Lewy body is. Rather, at present, the favored inter-
pretation is that it is a quantitative deviation of nor-
mal neuronal parameters in schizophrenia, probably
arising at least partly during development, and puta-
tively affecting functional connectivity between var-
ious brain regions. These hypotheses are elaborated
further below. However, it is important to remain
critical of the empirical data, which could equally
lead to the conclusion that, though brain structure is
clearly altered in schizophrenia, its location, nature,
and consequences remain largely unknown.
53
Neurochemistry of schizophrenia 
A wide range of neurochemical parameters have been
investigated in schizophrenia, both postmortem
54,55 and
in vivo.
56,57 Among a multitude of findings, four major
neurochemical systems have been most implicated:
dopamine,serotonin (5-HT),glutamate,and γ -aminobu-
tyric acid (GABA).
Dopamine
The dopamine hypothesis of schizophrenia has been
neurochemically preeminent for 40 years.
58,59 It received
support from various postmortem findings of increased
dopamine content and higher densities of dopamine D2
receptors in schizophrenia.
60 However, despite its
longevity,there is still no consensus as to precisely what
the dopamine hypothesis explains,nor the nature of the
supposed abnormality. There are two main difficulties.
First, antipsychotics have effects of their own on
dopaminergic parameters (eg, receptor densities), con-
founding studies of medicated subjects. Second, molec-
ular biology has revealed a large and complex dopamine
receptor family,increasing the potential sites and mech-
anisms of dysfunction.
Increased D2 receptor densities occur in patients with
schizophrenia,but it is unclear what proportion,if any,is
not attributable to antipsychotic medication.
61 Statistical
methods have been used to argue that there is a schizo-
phrenia-associated elevation,but this must be balanced
against positron emission tomography (PET) studies of
D2 receptors in drug-naive and first-episode cases, all
but one of which are negative.Recently,it has been sug-
gested that the “clustering”of D2 receptors is altered in
schizophrenia, with more of the receptors existing as
monomers rather than oligomers.
62 This situation has
two implications: it complicates interpretation of the
imaging data, since different ligands have differential
selectivity for these receptor states; and it means that
there could be alterations in the functional activity of
D2 receptors even without an increase in total receptor
number (eg, via G protein coupling). Expression of D1
and D3 receptors has also been reported to be changed
in schizophrenia in postmortem or in vivo studies, but
these reports are either unconfirmed or contradicted by
other studies.
63 Particular controversy has surrounded
the D4 receptor following a report that it was upregu-
lated several-fold in schizophrenia.
64 However,the result
appears to have been due to a D4-like site (perhaps
related to the D2 monomer/oligomer issue),not the true
D4 receptor,and the status of the latter in schizophrenia
is unknown.
63
In contrast to the equivocal and hard-to-interpret data
concerning dopamine receptors in schizophrenia, there
is emerging good evidence for alterations in dopamine
neurons.Several PET and single photon emission com-
puted tomography (SPECT) studies have shown ele-353
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vated striatal dopamine release in response to amphet-
amine in untreated,acutely psychotic patients,implying
a dysregulation and hyperresponsiveness of dopamine
neurons.
65There is also recent evidence that D2 receptor
occupancy is higher in schizophrenia, implying an
increased synaptic dopamine concentration; interest-
ingly, the magnitude of the elevation predicts response
to antipsychotic medication.
66Although the state-depen-
dent nature of the changes mandates in vivo rather than
postmortem studies,the latter can provide independent
and corroborative support; for example, an altered
dopaminergic innervation in schizophrenia may be an
anatomical correlate.
67
Serotonin (5-HT)
There are two well-replicated postmortem findings con-
cerning the 5-HT system in schizophrenia: a loss of the
serotonin 5-HT2A receptor expression from the frontal
cortex; and an increased density of 5-HT1A receptors.
63
Changes in the 5-HT transporter have also been report-
ed.Both of the receptor alterations have been found in
medication-free patients and are not reproduced in rats
by antipsychotics, suggesting that, unlike the dopamine
receptor findings,they are not primarily caused by drug
treatment.The 5-HT2A receptor data illustrate how post-
mortem studies suggest targets for in vivo ligand-based
imaging, since the data have led to three PET studies
of younger and unmedicated subjects,and also how post-
mortem data can clarify their interpretation.Only one of
the three imaging studies has replicated the decrease in 
5-HT2A receptors in the frontal cortex,
68 but this may
reflect methodological problems.That is,the cerebellum is
used as the reference region for the PET analysis, which
presupposes an absence of cerebellar 5-HT2A receptors,
but this may not be the case.
69 Hypotheses to explain the
role of 5-HT in schizophrenia include the trophic func-
tions of the 5-HT system in neurodevelopment, interac-
tions between 5-HT and dopamine, impaired 5-HT2A
receptor–mediated activation of prefrontal cortex,and 5-
HT2A receptors as candidate genes.
70-72
Glutamate
The observation that phencyclidine and other noncom-
petitive antagonists of the N-methyl-D-aspartate
(NMDA) subtype of glutamate receptor produce a psy-
chosis resembling schizophrenia has driven hypotheses
of glutamatergic dysfunction in the disorder.
73There are
now some postmortem data in schizophrenia to support
this proposal. For example, in the temporal lobe, gluta-
matergic markers are decreased,
74 with reduced expres-
sion of non–NMDA glutamate receptors.
75 In the pre-
frontal cortex, the alterations affect NMDA receptor
subunit mRNAs,
76 illustrating a regional and subtype
selectivity of the findings,which precludes a simple con-
clusion about the nature of the abnormality.
73,77 Putative
mechanisms of glutamatergic involvement in the disor-
der center on interactions with dopamine
78 and subtle
forms of excitotoxicity.
79
γ -Aminobutyric acid (GABA)
In addition to the excitatory pathology implied by glu-
tamatergic abnormalities,the major inhibitory transmit-
ter GABA has also been advocated, on the basis of
alterations in receptor expression seen in the hip-
pocampus and frontal cortex,
80-82 as well as a possible
loss
81 or decreased activity
83 of GABAergic neurons and
the loss of GABAergic presynaptic terminals mentioned
earlier.
47The latter studies illustrate the overlap between
neurochemical and structural aspects of pathology, and
emphasize that the one cannot be understood clearly
without knowledge of the other.For example,consider a
decrease in the density of a receptor present on the den-
dritic spines of pyramidal neurons in schizophrenia:does
this reflect a primary disturbance of the receptor,or is it
secondary to a loss of dendritic spines,a generalized dys-
function of the spines,or even a pathology of the neuron
itself? Postmortem studies have the unique potential to
allow all these possibilities to be addressed, and there-
fore the nature of the abnormalities in schizophrenia to
be understood; these advantages counterbalance, and
must be offset against, the many difficulties of post-
mortem research.
Methodological issues 
Postmortem studies of schizophrenia have an unenvi-
able reputation of being seriously flawed because of two
main sorts of artifact:those due to perimortem changes,
and those due to antipsychotic medication or other
treatments.
Perimortem confounders are a real but manageable
problem.
84 Depending on the parameter being mea-
sured, various individual factors are important. Forexample, for morphometric studies, the mode of tissue
fixation and processing is important, whereas neuro-
chemical and molecular targets are more affected by
mode of death and hypoxia/ischemia.A range of exper-
imental and statistical strategies are available to address
these factors,and to allow the effects of schizophrenia to
be distinguished from them.
85
Confounding by antipsychotic drugs is unavoidable, in
that virtually all schizophrenics have (and should have)
received treatment during life, and the majority are on
medication at the time of death. Such confounding is
greatest in two areas: for dopamine and other neuro-
chemical parameters, which are the target of the drugs;
and for neuropathological studies in the striatum and
substantia nigra, where there is clear postmortem and
experimental evidence that antipsychotics induce neu-
ronal and synaptic changes.
86 However,for other studies
and in other brain regions, antipsychotic effects are an
overemphasized problem. For example, for cortical
cytoarchitectural studies, no correlations have been
found with treatment,nor do the drugs have any effects
upon similar parameters in rat brain.
86
Conclusions
Postmortem studies in schizophrenia have contributed sig-
nificantly to the considerable,albeit partial,progress which
has been made towards understanding the neuropatho-
logical (Tables I to III) and neurochemical (Table IV)
characteristics of the disorder.Although imaging modali-
ties provide an increasingly powerful and diverse technical
armamentarium,in several key areas,there is no substitute
for direct examination of the brain. For instance, it is not
(yet) possible to measure neuronal size, synaptic termi-
nals, or neuronal gene expression in any other way. The
important thing is to apply each method judiciously and to
choose the appropriate range of techniques to allow inte-
gration of in vivo with postmortem data.
Beyond these simple issues of robustness and conver-
gence, contemporary postmortem studies of schizo-
phrenia are attempting to answer several questions
(Table V). First, what is the core neuropathology of
schizophrenia and in what sense is it specific? Features
such as decreased cortical volume and cytoarchitectural
abnormalities are certainly not unique to schizophre-
Basic research
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Transmitter Main postmortem findings Other supporting evidence
Dopamine • Increased density of D2 receptors • DA-releasing agents produce psychosis
• Decreased cortical DA innervation • All antipsychotics are D2 receptor antagonists
• Increased D4-like receptor binding • Increased striatal DA release in vivo
• Alterations in D3 receptor splicing
Glutamate • Decreased presynaptic markers • NMDA receptor antagonists produce
• Decreased HC AMPA and kainate receptor expression schizophrenia-like psychosis 
• Minor changes in FC NMDA receptor subunits • Roles of NMDA receptors in development
• Altered glutamate fibers in cingulate cortex and neurotoxicity
• Partial NMDA receptor agonists
have some therapeutic benefit
5-HT • Decreased FC 5-HT2A receptor expression • 5-HT2 agonists (eg, LSD) are psychotomimetic
• Increased FC 5-HT1A receptors • 5-HT2 receptor polymorphisms associated
• Increased 5-HT transporter affinity with schizophrenia and clozapine response
• Developmental and trophic roles of 5-HT • Atypical antipsychotics have high affinity
for several 5-HT receptors 
GABA • Decreased density of FC GABAergic terminals • Roles of GABA in stress and neurotoxicity
• Increased GABAA receptor binding in limbic areas
• Altered expression of FC GABAA receptor subunits
• Decreased FC expression of glutamic acid decarboxylase
• Altered density of cingulate GABAergic cells 
Table IV. Key postmortem findings concerning the major transmitter systems implicated in schizophrenia.
AMPA: amino-3-hydroxy-5-methyl-4-isoxazole propionic acid; DA: dopamine; FC: frontal cortex; GABA: γ -aminobutyric acid; HC: hippocampus; 5-HT: serotonin; LSD: lysergic acid
diethylamine; NMDA: N-methyl-D-aspartate.nia,overlapping with those observed in a range of other
conditions.
50 There could be a diagnostic lesion charac-
teristic of schizophrenia still going unrecognized,though
this is increasingly implausible. Or, it could be the pre-
cise combination of alterations, and their location and
timing,which produce schizophrenia.Some clarification
will emerge as other idiopathic and putatively neurode-
velopmental conditions, such as bipolar disorder
87 and
autism,
88 are investigated.A complete answer,however,
will also likely require identification of the causative
genes and a better understanding of the pathogenesis,
not just the pathology, of schizophrenia. At this point,
one reencounters the circular problem: the goal of the
research is to find a valid endophenotype, yet without
one the goal may be unattainable.
A second area to highlight concerns the relationship
between the structural abnormalities and the patho-
physiology of the disorder. Functional imaging and
neuropsychological data have led to the view that
aberrant functional connectivity between brain regions
underlies schizophrenia.
89,90 The question is whether
the neuropathological features represent its structural
and molecular basis,
6 since such dysconnectivity does
not necessarily require an anatomical substrate.
91 A
related question concerns which aspect of the clinical
syndrome is most related to the neuropathology. It
could be argued that structural lesions are inherently
more likely to relate to the cognitive (or negative)
symptoms, since these are more stable and persistent
than the positive psychotic symptoms—especially as
many brains examined come from patients who had
been in remission for many years. The neuropathol-
ogy could also be a trait marker of vulnerability to
schizophrenia rather than related directly to symp-
toms themselves, as is the case for many of the MRI
findings.The ability to answer these challenging ques-
tions will require a sustained and sophisticated
approach to postmortem schizophrenia research over
the next decade. ❑
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• Which of the cytoarchitectural and synaptic alterations are
robust?
• Is there a single pathology or several? 
• How are the structural and neurochemical findings related?
• Does the neuropathology underlie the aberrant functional
connectivity?
• Does the neuropathology relate to psychotic symptoms or
the cognitive deficits?
• Are the changes diagnostically specific?
Table V. Some questions for postmortem studies of schizophrenia.
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Estudios post mortem en la esquizofrenia
Por más de un siglo, los estudios post mortem han
tenido un papel central en la búsqueda de la
patología estructural y bioquímica de la esquizo-
frenia. Sin embargo, a pesar de este tiempo trans-
currido se han realizado escasos progresos.
Recientemente esta situación ha comenzado a
cambiar, facilitada por la aparición de metodo-
logías más poderosas y mejores diseños de inves-
tigación, y por la disponibilidad de imágenes cere-
brales que aportan información complementaria.
Como resultado de esto, ahora se puede concluir
claramente que existen alteraciones estructurales
cerebrales en la esquizofrenia que son intrínsecas
a esta enfermedad. El proceso neuropatológico
no es degenerativo, sino que implica un cambio
en la citoarquitectura normal del cerebro, proba-
blemente originado durante el desarrollo. Existen
evidencias neuroquímicas post mortem de altera-
ciones en algunos sistemas de transmisión entre
los que se incluyen la dopamina, el glutamato, la
serotonina y el ácido gama amino butírico
(GABA). Aquí se revisan los hallazgos cardinales
junto con una consideración acerca de los proble-
mas conceptuales y metodológicos que afrontan
los estudios post mortem de la esquizofrenia.
Données d'autopsie dans la schizophrénie 
Depuis plus d’un siècle, l'autopsie a joué un rôle
essentiel dans la recherche des anomalies patho-
logiques structurales et biochimiques de la schi-
zophrénie. Néanmoins, peu de progrès ont été
accomplis durant cette période. Cette situation a
commencé à évoluer récemment avec l’émergen-
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